Kim's Eye Hospital

ACTIVE

136 Yeongsin-ro Yeongdeungpo-gu, Seoul, 首尔特别市, South Koreakimeye.comPrivate11–50 employeesEstablished: 1962-01-01

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1962

Overview

Trial Phase Distribution

Phase

Trials

Phase 4

55.6%

Not Applicable

11.1%

Trial Status Distribution

Completed

77.8%

Not yet recruiting

11.1%

Unknown

11.1%

Clinical Trials

Trials sponsored by this organization (9)

Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

Phase 4

Not yet recruiting

interventional

Sep 202530 participants

Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

Phase 4

Completed

interventional

Oct 202435 participants

Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy

Phase 4

Completed

interventional

Dec 202230 participants

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Completed

observational

Dec 2022135 participants

Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Phase 4

Unknown

interventional

Feb 202130 participants

Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion

Completed

observational

Aug 2019512 participants

Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients

Not Applicable

Completed

interventional

Jan 201716 participants

Intravitreal Aflibercept for Submacular Hemorrhage

Phase 4

Completed

interventional

Dec 201529 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations